CIP2A Influences Survival in Colon Cancer and Is Critical for Maintaining Myc Expression

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Wiegering, Armin ^a,b   Pfann, Christina ^b   Uthe, Friedrich Wilhelm ^b   Otto, Christoph ^a   Rycak, Lukas ^c   Mäder, Uwe ^b   Gasser, Martin ^a   Waaga Gasser, Anna Maria ^a   Eilers, Martin ^b   Germer, Christoph Thomas ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PROTEIN KINASE B; REGULATOR PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; CIP2A GENE; COHORT ANALYSIS; COLON CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE SILENCING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR MECHANICS; ONCOGENE; OVERALL SURVIVAL; PATHOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

AUTOANTIGENS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE KINASES; MEMBRANE PROTEINS; POSTOPERATIVE PERIOD; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84885053768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075292     Document Type: Article

References (22)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. Cancer J Clin 61: 69-90.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, et al. (2010) Colorectal cancer. Lancet. 375: 1030-47.
3. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, et al. (2007) CIP2A inhibits PP2A in human malignancies. Cell 130: 51-62.
4. Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, et al. (2004) A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 6: 308-18.
5. Cancer Genome Atlas Network, (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-7.
6. Böckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, et al. (2009) MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst. 101(11): 793-805.
7. Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, et al. (2011) Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 105(7): 989-95.
8. Ren J, Li W, Yan L, Jiao W, Tian S, et al. (2011) Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br J Cancer 105(12): 1905-11.
9. Côme C, Laine A, Chanrion M, Edgren H, Mattila E, et al. (2009) CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 15: 5092-100.
10. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, et al. (2011) Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 117: 6660-8.
11. Zhao D, Liu Z, Ding J, Li W, Sun Y, et al. (2010) Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways. J Med Microbiol. 59: 259-65.
12. Liu J, Wang X, Zhou G, Wang H, Xiang L, et al. (2011) Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol Oncol. 122: 430-6.
13. Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A, et al. (2012) CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther. [Epub ahead of print].
14. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, et al. (2012) CIP2A Is a Predictor of Poor Prognosis in Colon Cancer. J Gastrointest Surg. [Epub ahead of print].
15. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, et al. (2009) Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res. 15: 7642-7651.
16. Fukazawa H, Uehara Y, (2000) U0126 Reverses Ki-ras-mediated Transformation by Blocking Both Mitogen-activated Protein Kinase and p70 S6 Kinase Pathways Cancer Research. 60: 2104-2107.
17. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, et al. (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 7: 2591-600.
18. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, et al. (2010) p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC Cell Death Differ. 17: 236-45.
19. Sansom OJ, Meniel VS, Muncan V, Phesse TJ, Wilkins JA, et al. (2007) Myc deletion rescues Apc deficiency in the small intestine. Nature 446: 676-9.
20. Huang CY, Wei CC, Chen KC, Chen HJ, Cheng AL, et al. (2012) Bortezomib enhances radiation-induced apoptosis in solid tumors by inhibiting CIP2A. Cancer Lett. 317: 9-15.
21. Chen KF, Yu HC, Liu CY, Chen HJ, Chen YC, et al. (2011) Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A. Mol Cancer Ther. 10: 892-901.
22. Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF, (2012) CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol. 48: 585-93.